share_log

Virpax Pharmaceuticals analyst ratings

Benzinga Analyst Ratings ·  Jun 9, 2022 09:22
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
06/09/2022 158.06% Maxim Group → $4 Initiates Coverage On → Buy

Virpax Pharmaceuticals Questions & Answers

What is the target price for Virpax Pharmaceuticals (VRPX)?

The latest price target for Virpax Pharmaceuticals (NASDAQ: VRPX) was reported by Maxim Group on June 9, 2022. The analyst firm set a price target for $4.00 expecting VRPX to rise to within 12 months (a possible 158.06% upside). 1 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Virpax Pharmaceuticals (VRPX)?

The latest analyst rating for Virpax Pharmaceuticals (NASDAQ: VRPX) was provided by Maxim Group, and Virpax Pharmaceuticals initiated their buy rating.

When is the next analyst rating going to be posted or updated for Virpax Pharmaceuticals (VRPX)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Virpax Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Virpax Pharmaceuticals was filed on June 9, 2022 so you should expect the next rating to be made available sometime around June 9, 2023.

Is the Analyst Rating Virpax Pharmaceuticals (VRPX) correct?

While ratings are subjective and will change, the latest Virpax Pharmaceuticals (VRPX) rating was a initiated with a price target of $0.00 to $4.00. The current price Virpax Pharmaceuticals (VRPX) is trading at is $1.55, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment